The Membrane Transport Proteins GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes an array of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field.
The 2026 Gordon Research Conference on Membrane Transport Proteins, “Membrane Transporters and the Gateway to Health & Disease,” will convene ~200 investigators from academia, industry, and medicine at the Renaissance Tuscany Il Ciocco, June 14–19 (trainee-led GRS, June 13–14). Membrane transporters comprise roughly 10 % of the human genome, yet fewer than 4 % are clinically exploited, despite their central roles in prevalent disorders, including autism, depression, ADHD, addiction, and diabetes, and in rare diseases such as Christianson syndrome and mucoviscidosis. Breakthroughs in cryo-EM, AI-driven structure prediction, live-cell biosensors, and human-derived disease models now make it possible to translate fundamental transporter biology into first-in-class therapeutics, creating a timely need for a forum that seamlessly links molecular mechanisms to clinical applications. The program’s nine themed sessions and two plenary lectures deliberately pair structural and mechanistic discoveries with pre-clinical and clinical perspectives, covering topics from vesicular neurotransmitter loading and blood–brain-barrier gateways to ABC/OCT1-mediated drug disposition. Interwoven “Technology Spotlight” talks and “Reality-Check” panels will showcase state-of-the-art methods while candidly addressing their limitations, establishing rigorous, field-wide standards. A 1.5-day, trainee-run Gordon Research Seminar, anchored by keynote mentors Drs. Sara Jones and Walter Boron, plus mentoring innovations such as “Scientist Speed-Dating” lunches and the forum Breaking the Mold: Overcoming Barriers to Career Advancement will foster an inclusive, supportive environment that cultivates the next generation of transporter scientists. Guided by three specific aims, catalyzing translational science, elevating rigor and reproducibility, and building a global workforce, the conference is poised to reveal new transporter ligands, biomarkers, and drug-delivery strategies; to disseminate best-practice methodologies; and to launch enduring mentorship networks. By uniting siloed disciplines in a confidential, off-the-record environment that encourages presentation of unpublished data, the 2026 GRC will accelerate transporter-based solutions for some of today’s most urgent unmet medical needs.
